BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) went up by 5.45% from its latest closing price compared to the recent 1-year high of $17.74. The company’s stock price has collected 2.33% of gains in the last five trading sessions. Press Release reported on 07/15/21 that BioCryst Announces Designs for REDEEM-1 and REDEEM-2 Pivotal Trials with BCX9930 as Oral Monotherapy for Patients with PNH
Is It Worth Investing in BioCryst Pharmaceuticals Inc. (NASDAQ :BCRX) Right Now?
Plus, the 36-month beta value for BCRX is at 2.58. Opinions of the stock are interesting as 9 analysts out of 11 who provided ratings for BioCryst Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $18.00, which is $1.65 above the current price. BCRX currently public float of 176.16M and currently shorts hold a 10.87% ratio of that float. Today, the average trading volume of BCRX was 3.55M shares.
BCRX’s Market Performance
BCRX stocks went up by 2.33% for the week, with a monthly jump of 2.20% and a quarterly performance of 46.17%, while its annual performance rate touched 216.57%. The volatility ratio for the week stands at 4.57% while the volatility levels for the past 30 days are set at 4.64% for BioCryst Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is 0.55% for BCRX stocks with a simple moving average of 61.88% for the last 200 days.
Analysts’ Opinion of BCRX
Many brokerage firms have already submitted their reports for BCRX stocks, with Cowen repeating the rating for BCRX by listing it as a “Outperform.” The predicted price for BCRX in the upcoming period, according to Cowen is $16 based on the research report published on March 01st of the current year 2021.
JP Morgan, on the other hand, stated in their research note that they expect to see BCRX reach a price target of $7. The rating they have provided for BCRX stocks is “Overweight” according to the report published on September 29th, 2020.
BCRX Trading at 5.54% from the 50-Day Moving Average
After a stumble in the market that brought BCRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -8.43% of loss for the given period.
Volatility was left at 4.64%, however, over the last 30 days, the volatility rate increased by 4.57%, as shares sank -2.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +23.78% upper at present.
During the last 5 trading sessions, BCRX rose by +2.33%, which changed the moving average for the period of 200-days by +360.06% in comparison to the 20-day moving average, which settled at $16.13. In addition, BioCryst Pharmaceuticals Inc. saw 117.99% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at BCRX starting from ABERCROMBIE GEORGE B, who sale 5,000 shares at the price of $15.69 back on Jul 15. After this action, ABERCROMBIE GEORGE B now owns 3,000 shares of BioCryst Pharmaceuticals Inc., valued at $78,450 using the latest closing price.
Hutson Nancy J, the Director of BioCryst Pharmaceuticals Inc., sale 23,333 shares at $16.86 during a trade that took place back on Jun 10, which means that Hutson Nancy J is holding 65,073 shares at $393,394 based on the most recent closing price.
Stock Fundamentals for BCRX
Current profitability levels for the company are sitting at:
- -952.90 for the present operating margin
- +90.59 for the gross margin
The net margin for BioCryst Pharmaceuticals Inc. stands at -1026.35. The total capital return value is set at -131.36, while invested capital returns managed to touch -195.22.
When we switch over and look at the enterprise to sales, we see a ratio of 61.66, with the company’s debt to enterprise value settled at 0.14. The receivables turnover for the company is 1.16 and the total asset turnover is 0.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.06.